Today, more than 30,000 people in the United States are living with cystic fibrosis (CF)– a genetic condition characterized by thick sticky mucous that blocks respiratory tracts and traps germs, leading to infections, inflammation, and other problems. CF is triggered by a faulty cystic fibrosis transmembrane conductance regulator (CFTR) protein. A class of drugs called CFTR modulators fix the protein’s action, but medications developed prior to last year had actually only been reliable in individuals with extremely particular anomalies. A new mix drug, FDA approved in October 2019, is supplying CF relief for patients with the most typical CF gene anomaly (F508 del)– estimated to represent 90% of people coping with the illness.
For additional information on the annual Leading 10 Medical Innovations list including descriptions, videos, and year-by-year contrasts visit: https://innovations.clevelandclinic.org/Programs/Top-10-Medical-Innovations
▶ Share this video with others: https://youtu.be/XXq6WA2ykR8
▶ Subscribe to learn more about Cleveland Center: https://www.youtube.com/user/ClevelandClinic?sub_confirmation=1